The Claim
In adults aged 45 years or older with preexisting cardiovascular disease and a body mass index (BMI) of 27 kg/m² or higher who do not have diabetes, once-weekly subcutaneous semaglutide at a dose of 2.4 mg reduces the incidence of major adverse cardiovascular events—defined as cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke—by 20% compared to placebo over a mean follow-up period of 39.8 months.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
A weekly injection of semaglutide (2.4 mg) helps lower the risk of serious heart problems like heart attack, stroke, or heart-related death by 20% in people over 45 who have heart disease and are overweight, but don’t have diabetes, compared to a fake treatment.
See the scientific wording
Once-weekly subcutaneous semaglutide at a dose of 2.4 mg reduces the incidence of major adverse cardiovascular events—including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke—by 20% in adults aged 45 or older with preexisting cardiovascular disease and a BMI of 27 or higher who do not have diabetes, compared to placebo, over a mean follow-up of 39.8 months.
What the research says
1 studyStudy: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
The study tested the exact same drug, dose, and patient group as described in the claim and found it reduced heart problems by 20%, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.